Roche CEO says Novo's Catalent buyout 'could be a problem' for smaller drugmakers
The groups behind the letter alleged that Novo Nordisk’s plant purchases could hinder not only the Danish drugmaker’s chief commercial rival, Eli Lilly, but also companies like Viking Therapeutics, Pfizer, Roche and AstraZeneca, who are working on their own metabolic offerings.
NFL News: Andy Reid's Chiefs sign a key veteran to help Patrick Mahomes, Travis Kelce The Ocean Has Massive Energy Reserves.
Roche's CEO, Thomas Schinecker, revealed that Europe likely has more mpox infection cases than reported. The company could ...
Swiss pharmaceutical giant Roche said Wednesday that it was increasing its capacity to produce diagnostic tests to detect ...
The CEO of Roche said he has been informed that more cases of mpox infection have occurred in Europe than previously reported ...
Roche CEO Thomas Schinecker announced a rise in mpox cases in Europe, with potential for expanding test kit production ...
Roche Holding AG said its third-quarter sales rose thanks to eye drug Vabysmo as well as medicines for cancer, hemophilia and ...
FRANKFURT: The CEO of pharmaceuticals giant Roche, opens new tab said authorities should block the takeover of contract drug ...
In August this year, the World Health Organization (WHO) declared the new form of the virus a global health emergency after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback